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ABSTRACT 
The formulate and evaluate Niosome drug delivery system for Clindamycin phosphate to increase its effectiveness by increasing penetration 
through skin and reducing its side effects Sorbitan esters which are Non-ionic surfactants was the key ingredient which forms vesicles upon 
hydration with aqueous media. Cholesterol was used to make vesicle stable and rigid. Different formulations were preparing by  using different 
sorbitan ester and changing the ratio of surfactant and Cholesterol. Clindamycin Phosphate is an antibiotic widely used for the treatment of 
acne. The pseudomonas colitis occurs with oral dosage form while in topical dosage forms it has side effects like irritation,  skin rash, itching etc. 
its topical bioavailability is also less. An attempt has been made to overcome these limitations for the preparation to prepare niosomes of 
clindamycin phosphate as well as for the enhanced delivery through skin by the variation in cholesterol level. Niosome were prepared by 
reverse phase evaporation method using span 60 as polymer. The compatibility of drug and polymer is analyzed by using FTIR and DSC 
method. There was no interaction detected by FTIR, DSC study. Further the prepared niosomes wer e evaluated for drug entrapment efficiency, 
drug content, and in vitro drug release. Amongst all the formulation batch 3 shows the best release when compared to other batch. SEM 
(Scanning electron microscopy) revealed that niosomes were spherical and porous. Finally it was concluded that clindamycin phosphate have 
been found suitable for controlled release formulation due to its bioavailability and biodegradability and thus lead to improved patient 
compliance. 
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INTRODUCTION 
In the past few decades, considerable attention has been 
focused on the development of drug delivery system (NDDS). 
The NDDS should ideally fulfill two prerequisites. Firstly, it 
should deliver the drug at a rate directed by the needs of the 
body, over the periods of treatment. Secondly, it should 
channel the active entity to action. Conventional dosage 
forms including prolonged release dosage forms are unable 
to meet desire action of product. At present, no available 
drug delivery system behaves ideally, but sincere attempts 
have made to achieve them through various types of novel 
approaches in drug delivery. Niosomes non-ionic surfactant 
vesicles are microscopic lamellar vesicles formed when non-
ionic surfactants (mainly of alkyl or dialkyl polyglycerol 
ether class) are added to cholesterol with subsequent 
hydration in aqueous media.Vesicular systems such as 
liposomes and niosomes are also widely used in cosmetic 
and skin care applications because of their ability to increase 
the stability of entrapped drugs, improved bioavailability of 
poorly absorbed ingredients and enhanced skin penetration 
Bacterial infection is one of the most continual and 
significant issue around the world especially Indians are 
genetically more prone to it.1 
Clindamycin Phosphate is an antibiotic widely used for the 
treatment of acne. The pseudomonas colitis occurs with oral 
dosage form while in topical dosage forms it has side effects 
like irritation, skin rash, itching etc. its topical bioavailability 
is also less. An attempt has been made to overcome these 
limitations for the preparation to prepare niosomes of 
clindamycin phosphate. Span 60 is most widely used as a 
carrier for various novel dosage forms mainly due to its 
characteristic to improve the solubility of poorly soluble 
drugs as well as to control the release of drugs by slow 
erosion.2, 3 
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MATERIAL AND METHODS 
Clindamycin phosphate was granted from M/S Glen-mark 
pharmaceuticals Pvt.Ltd, Baddi. Span 60 was obtained from 
Central drug house Pvt. Ltd., New Delhi Chloroform was 
obtained from Thermo Fisher Scientific India Pvt. Ltd., 
Mumbai. Methanol was obtained from Merck Speciliality 
Ltd., Mumbai. n-propanolol, Avantor Performance Materials 
India Ltd., Gujarat. 
Preformulation Studies: 
Preformulation study is the initial step in the development of 
both active pharmaceutical ingredient (API) and drug 
product. A preformulation study is an important mechanism 
for determination of physical and chemical properties of the 
drug before including it in formulation advancement. 
Preformulation studies are essential step for progress of 
safe, effective, and stable dosage form. Thus, in order to 
establish supreme condition for clinically useful delivery 
system, preformulation studies were executed. Valuable 
pharmaceutical dosage form development requires various 
preformulation guidelines. Preformulation studies include 
solubility, melting point, and partition coefficient.4, 5 the drug 
and excipient interaction studies were carried out by FT-IR 
and DSC. 
Determination of λmax: 
UV visible spectrophotometric method was used to gather 
structural information about chromophoric part of 
Clindamycin phosphate. 10 mg of the drug was dissolved in 
10 ml and further volume made up to 100 ml with distilled 
water, suitable dilutions were made. The spectra were 
reported in the range of 200-400 nm to establish absorption 
maxima of Clindamycin phosphate.6 
Fourier Transform Infra-Red (FT-IR) Spectroscopy:  
IR spectroscopy is most effective system for qualitative 
identification of compound. The necessary information 
regarding the group present in specific compound has been 
given by IR spectroscopy. IR study was executed by using 
Perkin Elmer Fourier transformed infrared 
spectrophotometer. The potassium bromide (KBr) disk 
technique was applied using 100 mg of spectroscopic grade 
dried KBr. KBr was ground into fine powder using a 
mortar/pestle and coagulate into disc under a hydraulic 
pressure at 10,000psi. Clindamycin phosphate and drug 
excipient mixture were deposited on the KBr disc with the 
help of a capillary tube. Each KBr disc was examined at a 
resolution of 400 cm-1 over the wavelength region of 4000 – 
400 cm-1 and characteristics bands were reported.7 
Differential Scanning Calorimetry (DSC)  
To analyze any possible correlation between the drug and 
the utilized additives, DSC thermo grams of pure drug 
(Clindamycin phosphate) and drug excipient mixture with 
additives were accomplished. The samples of 10 mg were 
taken and heated in open aluminum pans at a heating rate of 
10ºC/min in a 30ºC to 300ºC temperature range.8 
Preparation of standard curves of Clindamycin 
phosphate: 
By reading the instrument (UV-visible spectrophotometer) 
at 210 nm Clindamycin phosphate concentration in the 
solution was determined. The standard curves of 
Clindamycin phosphate were prepared in distilled water. 
 
 
Preparation of niosomes by reverse phase evaporation 
method:  
The niosomal formulations were prepared by Reverse phase 
evaporation method. Accurately weighed quantities of drug, 
non- ionic surfactant (Span60) and cholesterol were 
dissolved in sufficient quantity of solvent mixture 
(Chloroform: Methanol 2:1) to give a clear solution. The 
formulation containing the amount in ratios i.e. Drug 
clindamycin phosphate (100 mg), Span-60 (15mg), 
Cholesterol (10mg), Chloroform (20ml), Methanol (5ml). 
The resulting solution is poured into a 1000 ml rotary flask 
and evaporated under vacuum (20- 25mm Hg) at 60°±2°C 
with the rotation speed of 100 rpm to form a uniform thin 
dry film. The rotary flask was removed from the bath and 
allowed to return to room temperature. The thin film formed 
was hydrated with 20 ml of distilled water while rotating the 
flask at 50 rpm (gentle agitation) at a temperature 60°±2°C. 
The resulting niosomal suspension was stored in a tightly 
closed container in a refrigerator.9, 10 
Table 1: Formulation Code of Niosomes containing 
surfactant Span 60 
 
Characterization of Clindamycin phosphate loaded span 
60 niosomes: 
Determination of drug content: The amount of drug 
(100mg) in the formulation was determined by lysing the 
niosomes using50% n-propanol. 50 ml of the niosomal 
preparation was pipetted out; sufficient quantity of 50% n-
propanol was added and shaken well for the complete lysis 
of the vesicles. After suitable dilution with water containing 
10% Methanol, and drug used in the formulation 100 mg 
used, the absorbance of the solution was measured at 
210nm in the UV- Visible Spectrophotometer. The excipients 
mixture without the drug treated in the similar manner as 
the niosomal suspension was used as blank. The drug 
content was calculated.11 
Determination of Entrapment Efficiency: The entrapment 
efficiency of the formulations was determined by 
centrifuging 1 ml of the suspension diluted to 10 ml with 
distilled water at 15,000 rpm for 60 minutes at 4°C using 
high speed cooling centrifuge in order to separate niosomes 
from unentrapped drug. The free drug concentration in the 
supernatant was determined at 210nm using UV- Visible 
Spectrophotometer after suitable dilution, and drug used in 
the formulation 100 mg used. The percentage of drug 
entrapment in niosomes was calculated using the following 
formula.12 
% drug entrapment 
                                       
          
     
In- vitro dissolution studies: The release of Clindamycin 
phosphate form niosome was investigated in distilled water 
as dissolution medium (900ml) USP type1 apparatus .A 
sample of niosomes equivalent to100mg of clindamycin 
phosphate was taken in the basket. A speed 52 rpm and 
temperature of 37±0.5℃ was maintained throughout the 
experiment. At fixed intervals, aliquots (5ml) were 
withdrawn and replaced with fresh dissolution media. The 
 
Formulation 
Code 
 
Non- Ionic 
Surfactant 
Drug:                      
Surfactant: 
Cholesterol 
(M Moles) 
CLP 60-1 Span 60 1:1:1 
CLP 60-2 Span 60 1:2:1 
CLP 60-3 Span 60 1:3:1 
CLP 60-4 Span 60 1:4:1 
CLP 60-5             Span 60 1:5:1 
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concentration of drug released at different time intervals  to 
determine the absorbance of collected samples were 
analyzed spectrophotometrically at 210 nm using UV- 
Visible spectrophotometer, and drug used in the formulation 
100 mg used.13 
 Kinetics Modeling of Drug Dissolution Profiles 
To analysis the in vitro release data various kinetic models 
were used to describe the release kinetic. The dissolution 
profile of the all formulations was fitted to higuchi and 
Korsmeyer – Peppa’s model to ascertain the kinetic 
modeling of the drug release and mechanism of drug release. 
Zero Oder kinetics (Constant rate process) 
Drug dissolution from pharmaceutical dosage forms that do 
not disaggregate and release the drug slowly can be 
represented by following equation. 
                                         Ft= Kot 
Where ft is the fraction of drug dissolved in time t and Ko is 
zero order release constant. 
Pharmaceutical dosage form following this profile release 
the same amount of drug by unit of time and this is ideal 
method of drug release in order to achieve a 
pharmacological prolonged action. The following relation 
can in a simple way express this model. 
                                       Qt= Qo + Kot 
Where, Qt is the amount o drug dissolved in time t, Qo is 
initial amount of drug in solution and Ko is zero order 
release rate constant. Most of the time Qo = 0. 
Application: This relationship can be used to describe the 
drug dissolution of several types of modified release 
pharmaceutical dosage forms, as in the case of some 
transdermal systems, as well as matrix tablets with low 
soluble drugs in coated forms, osmotic systems, etc. 
First order kinetics (Linear kinetics): 
Rate is directly proportional to the concentration, of drug 
undergoing reaction i.e. greater the concentration, faster the 
reaction. The drug dissolution study was first proposed by 
Gibaldi and Feldman in 1967. The following relation in a 
simple way can be expressed as 
                                       In (Qt/Qo) = K1t 
or in decimal logarithm. 
                                       Log Qt= log Qo- K1t/2.303 
Where, Q1 is amount of drug dissolved in the time t, Qo is 
initial amount of drug in solution and K1 is first order 
release rate constant. In this way a graphic of decimal 
logarithm of the release amount of drug versus time will be 
linear. 
Application: This relationship can be used to describe the 
drug dissolution in pharmaceutical dosage forms such as 
those containing water-soluble drugs in porous matrices. 
Higuchi model: 
Higuchi described the release of drug insoluble matrix as a 
square root of time dependent processes based on Fickian 
diffusion. A large number of modified release dosage form 
contain some sort of matrix system. In such instance, the 
drug dissolved from the matrix. The dissolution pattern of 
the drug is dictated by water penetration rate (diffusion 
controlled). In higuchi model, a plot of % drug release versus 
square root of time is linear. 
                                                        Q= Kh t1/2 
Where, Kh is constant, t is time. 
Application: This relationship can be used to describe the 
drug dissolution from several types of modified release 
pharmaceutical dosage forms, as in the case of some 
transdermal systems and matrix tablets with water soluble 
drugs. 
Korsmeyer- Peppas model: 
To find the mechanism of drug release, drug release data 
was fitted in Korsmeyer –Peppas model, log of % cumulative 
drug release versus log of time. 
                                                 Mt/M∞= Ktn 
Where, Mt/M∞ is fraction of drug released at time t and K is 
rate constant, n is release exponent. 
 
Table 2: Interpretation of diffusion release mechanism from polymeric film 
     Release Exponent(n) Drug Release Mechanism Rate as a function of Time  
     0.5 Fickian Diffusion t-0.5 
     0.5<n<1.0 Anomalous Transport Tn-1 
     1.0 Case II Transport Zero order release 
    Higher than 1.0 Super case II Transport Tn-1 
    
Scanning Electron Microscope (SEM):  
Particle size of niosomes is very important characteristic. 
The surface morphology (roundness, smoothness, and 
formation of aggregates) and the size distribution of 
niosomes were studied by Scanning Electron Microscopy 
(SEM). One drop of niosomal system was mounted on clear 
glass stub, air dried and sputter-coated with gold palladium 
(Au/Pd) using a vacuum evaporator and examined using a 
scanning electron microscope equipped with a digital 
camera, at 15 or 20 kV accelerating voltage. The sizes of the 
vesicles were measured by scanning electron microscope.14 
Stability Studies: The stability studies of the optimized 
niosomal formulations were performed at different 
conditions of temperature and the effect on physical 
characteristics, entrapment efficiency and drug content was 
noted. The niosomal dispersions were kept in the air tight 
containers and stored at 4- 8°C, 25±2°C and 40±2°C for 45 
days and 2 ml samples were withdrawn every 15 days and at 
the end of 45 days. The samples were analyzed 
spectrophotometrically at λmax 210 nm after disrupting the 
vesicles with 50% n-propanol.15, 16 
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Optimization Of Process- Related Variables 
Effect of hydration time: 
The niosomal formulations containing Span 60 at different 
ratios and a fixed amount of cholesterol (1:1:1, 
1:2:1,1:3:1,1:4:1,1:5:1) were hydrated with 10 ml of distilled 
water for 30 minutes, 60minutes and 90 minutes. The vesicle 
formation and entrapment efficiency of the formulations 
were calculated by centrifugation method.   
Effect of Sonication time 
The Niosomal formulations containing Span 60 at different 
ratios and a fixed amount of Cholesterol (1:1, 2:1, 3:1, 4:1, 
5:1) were subjected to ultrasonic vibration using 
Ultrasonicator. To study the effect of sonication time, the 
formulations were subjected to sonication for various time 
intervals (1 min, 2 mins, 3 mins, 4 mins and 5 mins). The 
entrapment efficiency of the formulations was measured. 
RESULT AND DISCUSSION 
Preformulation Studies:  
Description: 
 Clindamycin phosphate was found to be white or almost 
white, crystalline powder.  
Solubility:  
Freely soluble in water; very slightly soluble in ethanol 
(~750 g/L) TS and acetone R, practically insoluble in 
dichloromethane R.  
 Category: Antibacterial drug. 
Melting Point:  
The calculated melting point of Clindamycin phosphate was 
found to be 114℃. This result is the same as reported in 
reference and helps in the identification and purity of the 
drug powder used in the study. 
Determination of absorption maxima: 
Absorption maxima of Clindamycin phosphate in distilled 
water were found to be 210nm which is similar to the 
pharmacopoeia standards. 
Fourier Transform Infra-Red Spectroscopy:  
The FT-IR spectrum of Clindamycin phosphate, span60 and 
their physical mixture evidenced various characteristics 
peaks which are showed in Fig 1, Fig 2.The spectra showed 
that the free Clindamycin phosphate and formulated 
Clindamycin phosphate were in resemblance that ratified 
that the obtained sample of Clindamycin phosphate was 
pure.
 
             
 
Figure 1: FT-IR spectrum of Clindamycin phosphate 
 
 
Figure 2: FT-IR spectrum of Clindamycin phosphate, Span60. 
 
Differential Scanning Calorimetry (DSC) studies  
Thermal characteristics of pure drug, polymer, and chitosan 
unloaded microspheres and chitosan drug loaded 
microspheres was examined by using DSC analysis which are 
showed in Fig 3, Fig 4. DSC analysis revealed that there is no 
interaction between polymer and drug. 
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Figure 3: DSC thermogram of Clindamycin phosphate 
 
Figure 4: DSC thermogram of drug loaded span60 niosomes. (CLP-3) 
 
Standard curve of Clindamycin phosphate in distilled 
water.  
Standard stock solution and standard working solutions 
were prepared in distilled water and standard curves were 
obtained by plotting the data. In fig.5 
 
Figure 5: Standard curve of Clindamycin phosphate in 
distilled water 
Formulation and evaluation of Clindamycin phosphate 
loaded span 60 niosomes.  
Niosomes were prepared by using Reverse phase 
evaporation method. Further the prepared niosomes were 
evaluated for drug content, and entrapment efficiency.in 
fig.6 
Table3.Drug Content and Entrapment Efficiency of 
Clindamycin phosphate Niosomes containing Span-60 
      Formulation 
Code 
% DRUG CONTENT 
           (% w/w)(DC) 
 
 
% ENTRAPMENT 
EFFICIENCY 
(% w/w)(EE) 
CLP – 1 55.02 68.25% 
CLP – 2 58.25 69.56% 
CLP – 3 59.02 70.25% 
CLP-4 70.25 72.52% 
CLP-5 71.02 74.25% 
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Figure 6: Drug Content and Entrapment Efficiency of Clindamycin phosphate Niosomes containing Span-60 
In- vitro dissolution studies  
The in- vitro dissolution studies of Clindamycin phosphate from niosomes was examined in distilled water.in fig.7-10 
                                          Table 4: Cumulative % drug permeated from optimized formulation 
 
 
S.No 
 
    
       TIME 
                   Cumulative % drug release 
Formulation Code 
   CLP-1 CLP-2 CLP-3 CLP-4 CLP-5 
1 0 0 0 0 0 0 
2 1 2.55 6.9 5.32 9.32 1.22 
3 2 6.22 9.987 9.34 17.34 5.33 
4 3 10.25 14.23 13.45 24.66 8.55 
5 4 14.25 28.25 17.34 31.09 10.55 
6 6 15.26 37.77 23.65 48.39 16.00 
7 8 25.14 41.35 29.56 57.76 19.00 
8 11 26.05 44.83 39.25 64.86 25.56 
9 14 30.56 48023 51.25 74.39 45.25 
10 17 42.27 56.82 62.54 78.76 53.68 
11 21 5705 65.86 79.54 83.05 65.29 
12 24 75.5 82.79 91.25 89.56 86.25 
 
 
 
Figure 7: In-vitro drug release profile of different Span 60 niosomes 
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Figure 8: Drug Release Kinetics of Optimized Formulation (First Order Kinetics) 
 
Figure 9: Drug Release Kinetics of Optimized Formulation (Higuchi Model) 
 
Figure 10: Drug Release Kinetics of Optimized Formulation (Korsmeyer – Peppas Model) 
Table5:  Release Kinetic of Clindamycin phosphate in batch   CLP-1-CLP-5 
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F.C.      Zero order First Order Higuchi Equation Korsmeyer Peppas 
 K0(mg/h) R2 K1(h-1) R2 K R2 N R2 
CLP – 1 2.78 0.9 -0.02 0.86 14.185 0.867 1.09 0.77 
CLP – 2 3.03 0.93 -0.025 0.866 16.55 0.877 1.09 0.82 
CLP – 3 3.68 0.96 -0.028 0.88 17.15 0.92 1.011 0.91 
CLP-4 3.69 0.97 -0.03 0.91 19.035 0.953 1.012 0.93 
CLP-5 3.73 0.99 -0.04 0.98 20.305 0.977 1.27 0.95 
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Scanning Electron Microscopy (SEM)  
Scanning electron microscopy revealed that the niosomes 
were spherical and porous. The surface of the was niosomes 
rough and exhibited the presence of pores in the drug loaded 
niosomes. The initial burst release of the drug during 
dissolution is mainly due to the presence of drug particles on 
the surface. Surface study of the after niosomes dissolution 
showed bigger pores indicating that pores are responsible 
for the drug release and the mechanism of the drug may be 
diffusion controlled in fig.11 
 
 
 
Figure11: Scanning electron microscopy of CLP -3span60 niosomes 
 
Stability studies of Clindamycin phosphate loaded Span 
60 niosomes: 
Optimum niosomes were exposed to accelerated storage 
conditions, 40ºC±2ºC/75%RH±5% for six months according 
to ICH guidelines for stability testing of new drug substances 
and products. Niosomes were characterized for physical 
appearance, drug content and in-vitro drug release at regular 
intervals. There was no change in the physical appearance of 
niosomes. Additionally there was no great difference in the 
drug content and in vitro release characteristics of drug. 
Thus result implies good stability of the formulation.
 
Optimization of Process Related Variables 
Effect of hydration time 
Table 6.Effect of Hydration Time on Entrapment Efficiency of CLP-3 
S. No. Hydration Time (minutes) Entrapment Efficiency (%w/w) 
   1.                30                  31.06 ±2.52 
   2.                45                  39.5 ±1.15 
   3.                60                  65.2 ±0.16 
   4.                75                  63.53 ±1.5 
   5.                90                  61.27 ±1.11 
*Mean± SD (n=3) 
The niosomal formulations were hydrated with 20 ml of 
distilled water for 30, 45, 60, 75 and 90 minutes. The 
parameters like vesicle formation and entrapment efficiency 
was studied. The results indicated that vesicles were not 
formed properly but resulted in aggregates with hydration 
time of 30 minutes. On increase in hydration time, the 
spherical vesicles were formed and the entrapment 
efficiency also increased with increase in hydration time 
from 30 minutes to 60 minutes. Further increase in the 
hydration time to 90 minutes did not produce any great 
impact on the entrapment efficiency. 
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Effect of Sonication time 
Table 7.Effect of Sonication Time on Entrapment Efficiency of CLP-3 
S. No. Sonication Time (minutes) Entrapment Efficiency (%w/w) 
1.                   0 46.06 ±0.124 
2.                   05 51.13 ±0.016 
3.                   10 62.90±0.040 
4.                   15 57.20 ±0.081 
5.                   20 55.20 ±1.11 
*Mean± SD (n=3) 
Formulations were sonicated three times for 5 minutes with 
2 sec running time and 1 sec interval. Spherical vesicles 
were not observed after 10 minutes of sonication. The 
entrapment efficiency decreased as sonication time 
increased above 10 minutes. Exposure to Ultrasound for 
more than 10 minutes damages the vesicles. 10 minutes of 
sonication resulted in uniform unilamellar vesicles.   
CONCLUSION 
This research affirmed that the controlled release of 
Clindamycin phosphate loaded span 60 niosomes can be 
attained by Reverse phase evaporation method using span 
60 as polymer. DSC and FTIR studies exposed that there is 
no interaction between the drug and polymer which implies 
that drug is congenial with polymer. The five batches were 
evaluated for drug content, drug loading and entrapment 
efficiency. The batch 3 (CLP-3) with the drug and polymer 
ratio (1:3.1) was considered to be superior which showed 
maximum drug content and entrapment efficiency and 
prolonged release of drug. The drug release from niosomes 
was affected by various span60 concentrations. Scanning 
Electron Microscopy (SEM) studies revealed that the 
niosomes were spherical and porous. The drug release was 
found to be in controlled manner from batch (CLP-3). 
Therefore, it was concluded that Clindamycin phosphate 
loaded span60 niosomes were found to be best in the 
treatment of acne with reduced the side effect on skin and 
better diagnosis in a controlled release mode.     
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